Genetically engineered models have advantages over xenografts for preclinical studies.
about
Murine models to evaluate novel and conventional therapeutic strategies for cancerGEMMs as preclinical models for testing pancreatic cancer therapiesUse of rodents as models of human diseasesMouse models of pancreatic cancerContemporary murine models in preclinical astrocytoma drug developmentMouse models in liver cancer research: A review of current literatureThe zebrafish as a model for studying neuroblastomaSTX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic miceAnimal Models of Chemical Carcinogenesis: Driving Breakthroughs in Cancer Research for 100 YearsEngineering cancer microenvironments for in vitro 3-D tumor models.High and low frequency subharmonic imaging of angiogenesis in a murine breast cancer modelRe-evaluate the effect of hyperbaric oxygen therapy in cancer - a preclinical therapeutic small animal model studyGuidelines for the welfare and use of animals in cancer research.Animal models in osteosarcoma.Toward 3D biomimetic models to understand the behavior of glioblastoma multiforme cellsSimilarity on neural stem cells and brain tumor stem cells in transgenic brain tumor mouse models.Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.P-Rex1 is required for efficient melanoblast migration and melanoma metastasis.Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted.Near-infrared fluorescence imaging using a protease-specific probe for the detection of colon tumors.Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip.A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma modelQuantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphomaAn estrogen-induced endometrial hyperplasia mouse model recapitulating human disease progression and genetic aberrations.Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions.miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.Relative Initial Weight Is Associated with Improved Survival without Altering Tumor Latency in a Translational Rat Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma and Transarterial Embolization.Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade gliomaGenetically engineered mouse models in cancer researchMolecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinomaUse of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer.New approaches to molecular cancer therapeutics.Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human diseaseA preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.Segmental Transarterial Embolization in a Translational Rat Model of Hepatocellular Carcinoma.Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
P2860
Q24673595-6F3BD423-F838-4705-91AB-43D6EDB374BEQ26781848-70582FF6-DA6D-4B71-B471-A9F96A4DA657Q26822856-E26A5630-CA9B-4EA7-B8FE-2C8046737E98Q26860574-5E2B01FC-C721-4DC8-9272-2F14033A4265Q27026937-774A18F6-ACD0-48FE-A30A-B2A50F83BCD5Q27490350-32A59D38-0A1E-48A0-B2DC-AC8FAFA95EB6Q28070309-3310886C-A20C-4FBD-A701-C68B3C64936AQ28536340-425C488F-37AC-4540-B48F-CBD8926A31E5Q28829867-58C1CCBE-1BC5-4772-9BAD-7744D40297ABQ30358020-57E16E48-D70F-4480-B2AC-D0E1A3B366B8Q30375548-FD779073-BFB4-47CE-876D-5159A1D07FA5Q30461128-A7BE0E12-9A06-4A53-8EC6-8C8E08CE12C8Q33903753-C347A069-61EA-499A-858D-9CF85C29D2EFQ33917772-4246024D-4616-4219-9938-C90B1CA3F4A5Q34025911-75953002-AC63-4B3D-897E-D96A94149613Q34095200-B1E67250-E140-4126-B10E-067BD1D39DB0Q34164758-CF0A343B-5E07-4AFA-BA8D-1CA1B99734D3Q34235334-A7B26108-3201-49E7-8092-3F118EBF92D6Q34394131-63B33B26-5B86-4003-9438-379A9BA35100Q34494056-FFE79AE1-35E6-4807-8874-780236BE45C8Q34613544-7401FCB4-E6FA-4A45-9524-1980954E777AQ34818301-C16A1452-8E9B-4AEF-9C3C-1145BF56063DQ35166319-538D473E-AFE9-42A4-A3C3-38A3340F7DCDQ35799358-10A166A2-E74D-43D6-9E78-E433508C9FC0Q35928907-D7B3F3C1-CEE5-4FFD-9C2D-AD1AF97D5DC9Q36125236-1442A81F-43F1-42B2-95E0-90FD9B3B6A47Q36368456-EB0DBCC2-A0A8-4293-AD06-4CF2FDAB7C34Q36369624-F767D401-5B9F-46A6-ABF7-23CD7D47C39EQ36477494-CD71A8A7-403A-477B-A9D8-05E0120571A1Q36484037-01EA580D-EA4A-434E-A107-1F5588B608F5Q36497718-C1074B40-B622-4A2D-A673-683692D853CDQ36511080-971DA2DA-E9A2-4EA7-8484-8485752F6A21Q36627745-2A89BD5F-0271-4DCB-B0CA-5B8CDF9FC579Q36654909-DD7A728B-FF95-4BD0-8833-F2E354DAF24BQ36665931-3F8AAC05-6811-4390-88FC-AB81488431D3Q36720962-69B95415-A66D-44F9-88AB-D90BF652F03EQ36851289-24CFE5E7-8420-433A-B310-EA1CB5F917D9Q36857866-AEA43195-2CC3-486A-AD4C-667715E18F79Q36866538-05C15F0B-744D-443D-AE98-2A8B0A2FF28AQ36901035-E9B09339-056C-49F5-AC45-75B5D8614744
P2860
Genetically engineered models have advantages over xenografts for preclinical studies.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Genetically engineered models have advantages over xenografts for preclinical studies.
@ast
Genetically engineered models have advantages over xenografts for preclinical studies.
@en
Genetically engineered models have advantages over xenografts for preclinical studies.
@nl
type
label
Genetically engineered models have advantages over xenografts for preclinical studies.
@ast
Genetically engineered models have advantages over xenografts for preclinical studies.
@en
Genetically engineered models have advantages over xenografts for preclinical studies.
@nl
prefLabel
Genetically engineered models have advantages over xenografts for preclinical studies.
@ast
Genetically engineered models have advantages over xenografts for preclinical studies.
@en
Genetically engineered models have advantages over xenografts for preclinical studies.
@nl
P1433
P1476
Genetically engineered models have advantages over xenografts for preclinical studies.
@en
P2093
Eric C Holland
Oren J Becher
P304
3355-8, discussion 3358-9
P356
10.1158/0008-5472.CAN-05-3827
P407
P577
2006-04-01T00:00:00Z